Skip to search formSkip to main contentSkip to account menu

ENMD 2076

Known as: ENMD-2076, ENMD2076 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

PyrazolesPyrimidines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Phase II clinical and molecular trial of oral ENMD-2076 in clear cell ovarian cancer (CCOC): A study of the Princess Margaret phase II consortium.
5522Background: CCOC is a rare chemoresistant subtype of OC. ENMD-2076 is an oral multi-target kinase inhibitor with… 
2016
2016
The radiosensitizing effect of the aurora kinase inhibitors, ENMD-2076, on canine mast cell tumours in vitro.
ENMD-2076 is an aurora kinase inhibitor that also has multi-target tyrosine kinase inhibitor properties. In this study, the mRNA… 
2014
2014
Phase II study of oral ENMD-2076 administered to patients with ovarian clear cell carcinoma: A trial of the Princess Margaret Phase II Consortium.
TPS5620 Background: Ovarian clear cell carcinoma (OCCC) represents nearly 15% of all epithelial ovarian carcinomas (EOC). This… 
2012
2012
[Killing effect of aurora kinase inhibitor ENMD-2076 on acute myelogenous leukemia cells].
OBJECTIVE To investigate the effect of aurora kinase inhibitor ENMD-2076 on human acute myelogenous leukemia (AML) cell lines… 
Review
2011
Review
2011
From cell biology to therapy: ENMD-2076 in the treatment of multiple myeloma
Introduction: Multiple myeloma (MM) remains incurable, indicating the need for continued investigation of innovative strategies… 
2010
2010
Assessment of the In vivo Antitumor Effects of ENMD-2076, a Novel Multitargeted Kinase Inhibitor, against Primary and Cell Line–Derived Human Colorectal Cancer Xenograft Models
Purpose: This in vivo study was designed to investigate the efficacy of ENMD-2076, a small-molecule kinase inhibitor with… 
2010
2010
A Phase I Study of ENMD-2076 In Patients with Relapsed or Refractory Leukemia
Abstract 3307 Background: ENMD-2076 is a novel, orally-active molecule that inhibits Aurora A kinase and FLT3, as well as… 
2010
2010
Clinical Activity of a Novel Multiple Tyrosine Kinase and Aurora Kinase Inhibitor, ENMD-2076, Against Multiple Myeloma: Interim Phase I Trial Results
Abstract 1957 Background: Despite recent improvements, MM remains incurable, indicating the need for continued investigation of… 
2009
2009
An open-label, dose escalation, safety, and pharmacokinetic study of ENMD-2076 administered orally to patients with advanced cancer.
3520 Background: ENMD-2076, a novel, orally-active antimitotic and antiangiogenic molecule inhibits Aurora A as well as tyrosine… 
2008
2008
The Novel Aurora Kinase Inhibitor ENMD-2076 Has Potent Single Agent Activity against Multiple Myeloma (MM) in Vitro and in Vivo, and Shows Synergistic Activity in Combination with Lenalidomide
ENMD-2076 is a novel, orally-active molecule that has been shown to have significant activity against Aurora A kinase as well as… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)